Physician profile
Shawn E Breeding
NPI 1073885216
$2,851.22
in general payments reported to CMS, 2019-2025
14 companies · $769 in 2025
The $769 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $179 · 2022: $735 · 2023: $637 · 2024: $531 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,937.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $594.12 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $456.74 | 2021-2025 | |
| Axsome Therapeutics, INC. | $451.23 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $282.15 | 2022-2025 | Austedo Xr, Austedo Xr |
| Neos Therapeutics, Lp | $249.06 | 2023 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Neurocrine Biosciences, INC. | $244.89 | 2022-2024 | Ingrezza |
| Alkermes, INC. | $242.32 | 2022-2025 | Lybalvi, Aristada |
| Ironshore Pharmaceuticals INC. | $133.13 | 2021 | |
| Lundbeck LLC | $74.25 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.49 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $31.05 | 2022 | |
| Vanda Pharmaceuticals INC. | $24.36 | 2024 | Hetlioz, Fanapt |
| Indivior INC. | $14.62 | 2021 | |
| Tempus Ai, INC | $13.81 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Breeding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.